DRUG QUANTITY MANAGEMENT POLICY – PER RX
POLICY: Bone Modifiers – Xgeva Drug Quantity Management Policy – Per Rx
• Xgeva® (denosumab subcutaneous injection − Amgen)
REVIEW DATE: 02/10/2025
INSTRUCTIONS FOR USE
THE FOLLOWING COVERAGE POLICY APPLIES TO HEALTH BENEFIT PLANS ADMINISTERED BY CIGNA COMPANIES. CERTAIN CIGNA
COMPANIES AND/OR LINES OF BUSINESS ONLY PROVIDE UTILIZATION REVIEW SERVICES TO CLIENTS AND DO NOT MAKE COVERAGE
DETERMINATIONS. REFERENCES TO STANDARD BENEFIT PLAN LANGUAGE AND COVERAGE DETERMINATIONS DO NOT APPLY TO THOSE
CLIENTS. COVERAGE POLICIES ARE INTENDED TO PROVIDE GUIDANCE IN INTERPRETING CERTAIN STANDARD BENEFIT PLANS
ADMINISTERED BY CIGNA COMPANIES. PLEASE NOTE, THE TERMS OF A CUSTOMER'S PARTICULAR BENEFIT PLAN DOCUMENT [GROUP
SERVICE AGREEMENT, EVIDENCE OF COVERAGE, CERTIFICATE OF COVERAGE, SUMMARY PLAN DESCRIPTION (SPD) OR SIMILAR PLAN
DOCUMENT] MAY DIFFER SIGNIFICANTLY FROM THE STANDARD BENEFIT PLANS UPON WHICH THESE COVERAGE POLICIES ARE BASED. FOR
EXAMPLE, A CUSTOMER'S BENEFIT PLAN DOCUMENT MAY CONTAIN A SPECIFIC EXCLUSION RELATED TO A TOPIC ADDRESSED IN A COVERAGE
POLICY. IN THE EVENT OF A CONFLICT, A CUSTOMER'S BENEFIT PLAN DOCUMENT ALWAYS SUPERSEDES THE INFORMATION IN THE
COVERAGE POLICIES. IN THE ABSENCE OF A CONTROLLING FEDERAL OR STATE COVERAGE MANDATE, BENEFITS ARE ULTIMATELY
DETERMINED BY THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT. COVERAGE DETERMINATIONS IN EACH SPECIFIC INSTANCE
REQUIRE CONSIDERATION OF 1) THE TERMS OF THE APPLICABLE BENEFIT PLAN DOCUMENT IN EFFECT ON THE DATE OF SERVICE; 2) ANY
APPLICABLE LAWS/REGULATIONS; 3) ANY RELEVANT COLLATERAL SOURCE MATERIALS INCLUDING COVERAGE POLICIES AND; 4) THE
SPECIFIC FACTS OF THE PARTICULAR SITUATION. EACH COVERAGE REQUEST SHOULD BE REVIEWED ON ITS OWN MERITS. MEDICAL
DIRECTORS ARE EXPECTED TO EXERCISE CLINICAL JUDGMENT AND HAVE DISCRETION IN MAKING INDIVIDUAL COVERAGE
DETERMINATIONS. COVERAGE POLICIES RELATE EXCLUSIVELY TO THE ADMINISTRATION OF HEALTH BENEFIT PLANS. COVERAGE POLICIES
ARE NOT RECOMMENDATIONS FOR TREATMENT AND SHOULD NEVER BE USED AS TREATMENT GUIDELINES. IN CERTAIN MARKETS,
DELEGATED VENDOR GUIDELINES MAY BE USED TO SUPPORT MEDICAL NECESSITY AND OTHER COVERAGE DETERMINATIONS.
CIGNA NATIONAL FORMULARY COVERAGE:
OVERVIEW
Xgeva, a receptor activator of nuclear factor kappa-B ligand inhibitor, is indicated
for the following uses1:
• Giant cell tumor of bone, treatment of adults and skeletally mature
adolescents with disease that is unresectable or where surgical resection is
likely to result in severe morbidity.
• Hypercalcemia of malignancy, treatment of, that is refractory to
bisphosphonate therapy.
• Skeletal-related events, prevention of, in patients with multiple myeloma
and in those with bone metastases from solid tumors.
Another injectable formulation of denosumab, Prolia®, is available, but it is not
included in this policy.2
Dosing
• Giant Cell Tumor of Bone and Hypercalcemia of Malignancy: 120 mg
given by subcutaneous injection once every 4 weeks with additional doses of
120 mg on Days 8 and 15 of the first month of therapy.
Page 1 of 3 - Cigna National Formulary Coverage - Policy:Bone Modifiers – Xgeva Drug Quantity Management
Policy – Per Rx
• Skeletal-related events: 120 mg given by subcutaneous injection once every
4 weeks.
Availability
Xgeva is available as a 120 mg/1.7 mL single-dose vial.1
POLICY STATEMENT
This Drug Quantity Management program has been developed to promote the safe,
effective, and economic use of Xgeva. If the Drug Quantity Management rule is not
met for the requested medication at the point of service, coverage will be
determined by the Criteria below. “One-time” approvals are provided for 30 days in
duration.
Drug Quantity Limits
Product Strength and Form Retail Home Delivery
Maximum Maximum
Quantity Quantity
per Rx per Rx
Xgeva® 120 mg/1.7 mL single- 1.7 mL (1 vial) 5.1 mL (3 vials)
(denosumab subcutaneous dose vial
injection)
Bone Modifiers – Xgeva Drug Quantity Management Policy – Per Rx
product(s) is(are) covered as medically necessary when the following
criteria is(are) met. Any other exception is considered not medically
necessary.
CRITERIA
1. If the patient has giant cell tumor of bone and is initiating therapy, approve a
one-time override for 5.1 mL (3 vials) at retail or home delivery.
2. If the patient has hypercalcemia of malignancy and is initiating therapy or is
repeating treatment (up to six times per year), approve a one-time override 5.1
mL (3 vials) at retail or home delivery.
REFERENCES
1. Xgeva® subcutaneous injection [prescribing information]. Thousand Oaks, CA: Amgen; June
2020.
2. Prolia® subcutaneous injection [prescribing information]. Thousand Oaks, CA: Amgen; March
2024.
3 Pages - Cigna National Formulary Coverage - Policy:Bone Modifiers – Xgeva Drug Quantity Management Policy
– Per Rx
HISTORY
Type of Summary of Changes Review
Revision Date
Early Annual Policy was updated to reflect the existing quantity limits when a product 01/23/2023
Revision is obtained via home delivery.
Annual No criteria changes. 02/07/2024
Revision
Annual Policy statement was updated to note that “one-time” approvals are 02/10/2025
Revision provided for 30 days in duration.
Updated criteria to remove “the requested quantity, not to exceed.”
"Cigna Companies" refers to operating subsidiaries of The Cigna Group. All products and services are
provided exclusively by or through such operating subsidiaries, including Cigna Health and Life
Insurance Company, Connecticut General Life Insurance Company, Evernorth Behavioral Health, Inc.,
Cigna Health Management, Inc., and HMO or service company subsidiaries of The Cigna Group. ©
2025 The Cigna Group.
3 Pages - Cigna National Formulary Coverage - Policy:Bone Modifiers – Xgeva Drug Quantity Management Policy
– Per Rx